TITLE

Effect of antihyperglycaemic agents added to metformin and a sulfonylurea in type 2 diabetes

PUB. DATE
November 2011
SOURCE
Australian Journal of Pharmacy;Nov2011, Vol. 92 Issue 1098, p90
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article examines the effect of adding a third antihyperglycaemic drug (AHD) to the ongoing metformin and sulfonylurea medication, when blood glucose control is not achieved in patients with type 2 diabetes. Results of studies conducted to evaluate the effect of AHD on glycemic control and weight gain in type 2 diabetes' patients concluded that the drug classes did not differ in effect on HbA1c level. A list of available medicines for diabetes in Australia is provided.
ACCESSION #
69615440

 

Related Articles

  • Effect of rosemary on fasting blood glucose, hemoglobin A1c and Vitamin B12 in healthy person and Type 2 diabetic patients taking glucomid or/and metformin. Shawabkeh, Mahmoud Jumah Al; Jamal, Abdulrahim Al // National Journal of Physiology, Pharmacy & Pharmacology;2018, Vol. 8 Issue 1, p87 

    No abstract available.

  • Clinical experience with liraglutide in 196 diabetics from atertiary care centre in India. Mishra, S. K.; Kaur, K.; Makkar, A.; Saxena, M.; Wasir, J. S.; Bansal, B.; Sharma, P.; Singh, P.; Mithal, A. // Indian Journal of Endocrinology & Metabolism;Dec2012 Supplement, Vol. 16, pS521 

    Background: Majority of patients with type 2 diabetes does not achieve glycemic goals. Weight gain and hypoglycemia are two most common adverse effects of currently available antidiabetic medications. Aims of the Study: (1)To evaluate the effect of liraglutide on glycemic control and weight in...

  • Linagliptin Noninferior to Glimepiride in Diabetics Failing Metformin.  // International Cardiovascular Research Journal;2012, Vol. 6 Issue 2, p67 

    The article focuses on a study published on June 27, 2012 in "Lancet," which suggested that the use of the dipeptidyl peptidase-4 (DPP-4) inhibitorlinagliptin is as effective as asglimepiride in treating diabetic patients who are inadequately controlled with metformin. Lead investigator Doctor...

  • Low-dose guar improves diabetic control. Jones, D. B.; Lousley, S.; Jelfs, R.; Slaughter, P.; Carter, R. D.; Mann, J. I. // Journal of the Royal Society of Medicine;Jul1985, Vol. 78 Issue 7, p546 

    Twenty diabetic outpatients (12 non-insulin-treated and 8 insulin-treated) were given guar granulate in a dose of 10 g daily for two months in order to study the effect on glycaemic control and lipid levels. Mean glycosylated haemoglobin levels (HbA1c%) fell from 1.1± 2.0% pre-guar to 10.5...

  • Clinical Experience With the Addition of Pramlintide in Patients With Insulin-Requiring Type 2 Diabetes. Elkind-Hirsch, Karen; Butler, William J.; Bhushan, Madhu; Hirsch, David; Bhushan, Rajat // Diabetes Care;Jan2008, Vol. 31 Issue 1, p39 

    The article focuses on a study that involved adding pramlintide in patients with insulin-requiring type 2 diabetes. According to it, pramlintide added to insulin treatment in patients with type 2 diabetes was shown to reduce postprandial glucose levels, improve glycemic control, and promote...

  • Unexpectedly low HbA1c levels in two diabetes patients following dapsone use. Unnikrishnan, Ranjit; Anjana, Ranjit Mohan; Jayashri, Ramamurthy; Mohan, Viswanathan // Indian Journal of Endocrinology & Metabolism;Jul/Aug2012, Vol. 16 Issue 4, p658 

    The article describes the cases of two patients with type 2 diabetes patient who had inappropriately low gycated hemoglobin (HbA1c) levels following chronic administration of dapsone. The first patient initially received oral antidiabetic drugs. He was given multidrug therapy, including dapsone,...

  • Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes. Phung, Olivia J.; Scholle, Jennifer M.; Talwar, Mehak; Coleman, Craig I. // JAMA: Journal of the American Medical Association;4/14/2010, Vol. 303 Issue 14, p1410 

    The article offers information on a study which investigated the comparative efficacy, risk of weight gain and hypoglycemia linked with noninsulin antidiabetic drugs in patients with type 2 diabetes mellitus not controlled by metformin alone. A detailed description of study selection, data...

  • Exenatide: A New Promising Antidiabetic Agent. CHAKRABORTI, C. K. // Indian Journal of Pharmaceutical Sciences;Jan/Feb2010, Vol. 72 Issue 1, p1 

    Exenatide is a unique agent which can effectively control blood glucose levels in type 2 diabetes mellitus without producing dangerous adverse effects. In addition, it can lower body weight which is very essential for the treatment of obese type 2 diabetes mellitus patients. Since it can delay...

  • Haemoglobin A1c Goal Attainment in Relation to Dose in Patients with Diabetes Mellitus Taking Metformin. Penning-van Beest, Fernie J. A.; Wolffenbuttel, Bruce H. R.; Herings, Ron M. C. // Clinical Drug Investigation;2008, Vol. 28 Issue 8, p487 

    Background and objective: Conclusions from clinical trials suggest possible therapeutic advantages for once-daily agents over twice-daily agents in the treatment of type 2 diabetes mellitus. This study set out to investigate the relationship between metformin dosing frequency and glycosylated...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics